Medable, Inc., a Palo Alto, Calif.-based platform for decentralized clinical trials, raised $25m in funding.
The round, which brought total capital raised to more than $45m, was led by GSR Ventures, with participation from existing investor PPD, Inc. In conjunction with the funding, Dr. Sunny Kumar, partner at GSR Ventures, joined the Medable board.
The company intends to use the funds to accelerate clinical drug development with digital technology, partnerships and market adoption for its decentralized trial platform.
Led by Dr. Michelle Longmire, CEO and co-founder, Medable provides a global decentralized trial platform that streamlines design, recruitment, retention and data quality, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. The platform connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. It is now used by leading biopharma sponsors and clinical research organizations worldwide, and has been used for trials in 30+ countries and 26 languages.